

Quanterix

Quanterix' Simoa Technology to Broaden RayBiotech Immunoassay Services

Quanterix partners with RayBiotech to provide ultrasensitive single molecule array technology to support biomarker research

Lexington, Mass. – March 31, 2015 — [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that RayBiotech, Inc., of Norcross, GA, has adopted its [Simoa](#) technology to deploy as part of their innovative solutions for biomarker discovery and testing.

“Given RayBiotech’s longstanding reputation as a leader in the development of protein detection products, it is only fitting to work with Quanterix,” said Dr. Ray Ruopan Huang, Co-founder and CEO, RayBiotech. “With Simoa’s 100 to 1,000 fold increase in sensitivity over standard protein detection techniques coupled with RayBiotech’s target specific content, this service has the potential to transform our understanding of numerous diseases. We look forward to using the Simoa platform as a new tool at RayBiotech for the ultrasensitive detection of protein biomarkers.”

RayBiotech will leverage its extensive catalog of antibodies and experience with developing protein assays to offer its customers services that complement Quanterix’ own [Simoa Accelerator](#) offering based in Lexington, MA. The Simoa Accelerator lab allows researchers to access its technology to run their samples on Simoa assays, convert their existing assays to Simoa for greater sensitivity, or to have custom assays developed by the Quanterix team for specific markers of interest.

“Understanding the incredible role of quantifying ultra-low concentrations of protein biomarkers in human samples and their linkage to the complex mechanisms of a disease has the potential to revolutionize the field of medicine as we know it,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “We are very pleased to be collaborating with RayBiotech and to work together to provide access to these important new developments in healthcare.”

To learn more about Simoa, please visit: <http://www.quanterix.com/simoa-is-here>.

About RayBiotech, Inc.

In 2001, RayBiotech (<http://www.raybiotech.com>) introduced the first commercially available cytokine antibody array with a focus on translating scientific knowledge into improved health. RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are manufactured under GMP compliance and ISO 13485:2003 certification and are featured in thousands of publications, including: Nature, Nature Medicine, Science, Cell, Lancet, PNAS and many others. Offering the world’s largest selection of antibody and protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta (Norcross, GA).

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing

applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: <http://www.quanterix.com>.

###

Contacts:

Nikki Festa & Caitlyn Keating

PAN Communications

617-502-4300

quanterix@pancomm.com